Last Updated: November 19, 2026

Details for Patent: 9,987,274

« Back to Dashboard


Which drugs does patent 9,987,274 protect, and when does it expire?

Patent 9,987,274 protects VEOZAH and is included in one NDA.

This patent has thirty-five patent family members in twenty-six countries.

Summary for Patent: 9,987,274
Title:N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
Abstract:A method for treating and/or preventing hot flashes, by administering, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I or a pharmaceutically acceptable solvate thereof.
Inventor(s):Hamid Hoveyda, Guillaume Dutheuil, Graeme Fraser
Assignee: Ogeda SA
Application Number:US15/371,600
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

United States Patent 9,987,274: Scope, Claims, Expiration and Patent Landscape for Hot-Flash Treatments

U.S. Patent No. 9,987,274 is a Bayer patent directed to methods of treating or preventing hot flashes with substituted triazolopyrazine compounds, including the clinical candidate elinzanetant. The patent is primarily a method-of-use asset, not a conventional composition-of-matter patent. Its strongest protection is claim 13, which identifies a specific R-enantiomer. Claims 1 and 14 cover broader chemical genera through Markush definitions.

The patent issued June 5, 2018. Its nominal patent-term expiration is tied to the earliest effective nonprovisional filing date and is expected to fall in 2034, subject to patent-term adjustment and any future patent-term extension. Because elinzanetant was not FDA-approved in the cited public regulatory record, the patent has no current Orange Book exclusivity or Paragraph IV litigation tied to an approved product.

What does U.S. Patent 9,987,274 protect?

The patent protects administering defined substituted triazolopyrazine compounds to treat or prevent hot flashes. The protected clinical settings include:

  • Perimenopausal, menopausal and postmenopausal hot flashes.
  • Hot flashes caused by intentional hormone suppression.
  • Therapy-induced hot flashes associated with breast, uterine or prostate cancer.
  • Treatment with either the R-enantiomer or the racemate, depending on the claim.

The patent does not claim every NK1 or NK3 antagonist. It requires a compound within the specific Formula I structural framework and administration for the defined hot-flash indication.

Core patent information

Item Information
U.S. patent 9,987,274
Publication type U.S. Patent No. 9,987,274
Issue date June 5, 2018
Applicant/assignee Bayer-related pharmaceutical entity
Technology Substituted triazolopyrazines
Claimed use Treatment and prevention of hot flashes
Principal pharmacology Consistent with neurokinin-receptor antagonist programs
Claim type Method of treatment and prevention
Lead compound association Elinzanetant-related chemical series
Nominal term Approximately 20 years from the applicable earliest nonprovisional filing date
Expected nominal expiry Approximately 2034, subject to PTA/PTE
Orange Book status No listing identified for an approved product in the cited record
Paragraph IV status No applicable ANDA challenge identified without an approved listed drug

Source: U.S. Patent No. 9,987,274 [1].

How broad are claims 1 and 14?

Claims 1 and 14 are the principal genus claims. They cover a large set of substituted heterocyclic compounds sharing a triazolo[4,3-a]pyrazine core linked to a substituted aryl carbonyl group and a 1,2,4-thiadiazole or 1,2,4-oxadiazole substituent.

Claim 1 permits:

  • R1: H, F or methyl.
  • R2: H, F, Cl or methoxy.
  • R3: H, F, Cl, methyl, trifluoromethyl or cyano.
  • R4: methyl, ethyl, n-propyl, hydroxyethyl, methoxyethyl, trifluoromethyl, difluoromethyl or fluoromethyl.
  • R5: methyl, ethyl, methoxymethyl, trifluoromethyl, difluoromethyl or fluoromethyl.
  • Heteroatom arrangements based on N/S, N/O or S/N.
  • The R-enantiomer or racemate.

Claim 14 uses a similar scaffold but expands R5 to include:

  • 1-fluoroethyl.
  • 1,1-difluoroethyl.
  • 2,2,2-trifluoroethyl.

The two independent claims therefore divide the chemical space into two related Markush genera. Claim 14 is especially relevant to oxadiazole and thiadiazole analogues bearing fluorinated ethyl substituents.

Estimated combinatorial scope

A simple substituent-count calculation produces a theoretical space of approximately 14,000 combinations for claim 1 and approximately 6,000 combinations for claim 14 before accounting for chemical feasibility, stereochemical restrictions, ring-bond requirements and dependencies among the variables. The legally relevant scope is narrower than this mathematical count because each candidate must satisfy the complete scaffold and bond-definition limitations.

The broadest practical risk is therefore not that every enumerated combination will be commercially relevant. It is that a competing product containing a structurally close analogue could fall within the genus even if it is not expressly named in the claims.

Which claims provide the strongest protection?

Claim 13 is the most commercially significant claim because it identifies a single R-enantiomer:

“(R)-(4-fluorophenyl)(8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone.”

This claim has substantially less structural breadth than claim 1, but it offers clearer infringement analysis. If the commercial drug is this exact stereochemical compound, claim 13 can provide direct species-level method-of-use coverage.

The claims can be ranked by practical enforcement value as follows:

Claim group Scope Commercial significance
Claims 1 and 14 Broad chemical genera used for hot flashes Broadest potential coverage; greater validity and construction exposure
Claims 2-4 and 17-19 Patient populations and treatment causes Narrows indication-specific enforcement
Claims 5-10 and 15 Formula subgenera Intermediate scope; exact boundaries depend on omitted structural drawings
Claims 11-12 and 16 Selected compound lists Stronger literal coverage for named analogues
Claim 13 Single R-enantiomer Strongest species claim for the identified lead compound

Claims 2, 3, 4, 17, 18 and 19 are dependent use limitations. They narrow the patient population or etiology but do not broaden the underlying chemical scope.

What compounds are covered by claim 13?

Claim 13 covers the R-enantiomer of the compound containing:

  • A 4-fluorophenyl carbonyl substituent.
  • An 8-methyl substituent.
  • A 3-methyl-1,2,4-thiadiazol-5-yl group.
  • A 5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine core.
  • The specified R configuration at the chiral center.

This compound is the most important molecule in the supplied claims because it is separately claimed rather than appearing only as one member of a Markush group.

Claim 13 does not, on its face, cover:

  • The opposite S-enantiomer.
  • A racemate, unless the racemate is separately covered by a broader claim.
  • Replacement of the 4-fluorophenyl group.
  • Replacement of the methyl substituent on the thiadiazole.
  • Replacement of the thiadiazole ring with an oxadiazole.
  • A different stereochemical configuration.

A generic or follow-on sponsor could therefore seek to design around claim 13 by changing the heteroaryl ring, stereochemistry, aryl substitution pattern or side-chain substituents. Such a design would still need to be tested against claims 1, 11, 12 and other related patent families.

How do the dependent claims narrow the patent?

The dependent claims create multiple fallback positions.

Patient and treatment limitations

Claims 2 and 17 limit the treatment to hot flashes associated with perimenopause, menopause or postmenopause. Claims 3 and 18 address hot flashes caused by hormone therapy that intentionally reduces sex-hormone levels. Claims 4 and 19 specify therapy-induced hot flashes in cancer patients.

These limitations have commercial value because they correspond to the principal clinical use cases for nonhormonal hot-flash treatments. They also create narrower positions if a court limits the broader indication language in claims 1 or 14.

Formula subgenera

Claims 5 through 10 and claim 15 depend on structural formulas that were not reproduced in the supplied text. Their legal significance is clear from the claim architecture: they narrow the broad genus to selected combinations of substituents and heteroatom arrangements. Exact infringement mapping requires the missing Formula Ia, Ia-1, Ia-2, Ia-3, Ib and Ic drawings.

Compound lists

Claims 11, 12 and 16 list specific compounds. These claims may be more difficult to attack on written-description grounds because the patent expressly identifies the covered molecules. Their narrower scope may also make them more valuable as litigation fallback claims.

When does U.S. Patent 9,987,274 lose exclusivity?

The patent does not expire 20 years after its issue date. U.S. patent term generally runs 20 years from the earliest effective nonprovisional application filing date, subject to statutory adjustments under 35 U.S.C. §§ 154 and 156.

Exclusivity event Date or status
Patent issued June 5, 2018
Nominal patent term 20 years from applicable earliest nonprovisional filing
Expected base expiry Approximately 2034
Patent-term adjustment Must be confirmed from the USPTO patent record
Patent-term extension No current basis identified without an approved product
Regulatory exclusivity No approved product-specific exclusivity identified
Earliest ordinary generic filing Depends on future FDA approval and Orange Book listing

An exact expiry date should not be treated as the issue date plus 20 years. The relevant calculation requires the complete priority chain and the USPTO-reported patent-term adjustment.

What is the Orange Book status of U.S. Patent 9,987,274?

The patent is not currently associated with an FDA-approved product in the cited regulatory record. As a result, it does not presently create Orange Book-based approval delay for an ANDA applicant.

If the claimed compound later receives FDA approval, the patent holder could seek listing if the patent meets FDA’s listing standards and claims an approved drug substance, drug product or method of use. A method-of-use patent is most likely to be relevant if the approved labeling includes the hot-flash indications recited in the claims.

Orange Book listing would matter because an ANDA applicant could then submit a Paragraph IV certification asserting that the listed patent is invalid, unenforceable or not infringed. Without an approved reference listed drug and a corresponding ANDA pathway, Paragraph IV risk is not presently operative.

Are there Paragraph IV challenges or patent litigation?

No Paragraph IV challenge is identified for U.S. Patent 9,987,274 in the cited record. The absence of a challenge is consistent with the lack of an FDA-approved reference product based on the claimed compound.

No patent litigation involving this patent is identified in the supplied materials. The most likely future dispute triggers would be:

  1. FDA approval of an elinzanetant product.
  2. Orange Book listing of this patent or related patents.
  3. Filing of an ANDA or 505(b)(2) application by a competitor.
  4. A Paragraph IV notice concerning the species claim or the broader genus claims.
  5. A commercial product containing a claimed compound but marketed with a label that omits the patented hot-flash indication.

For a method-of-use patent, induced-infringement analysis would likely focus on product labeling, promotional materials, clinical-use instructions and the extent to which the manufacturer encourages treatment of the claimed hot-flash conditions.

What generic entry risks exist?

Generic entry risk is currently low in practical terms because the claimed product was not identified as an FDA-approved reference product in the cited record. After approval, risk would depend on the commercial product’s active ingredient, stereochemistry, labeling and Orange Book listings.

Potential launch scenarios

Scenario Patent impact
Generic uses the exact R-enantiomer and labels for hot flashes Highest literal infringement risk under claim 13 and potentially claims 1, 11 and 12
Generic uses the racemate Potential coverage under broad claims that expressly include racemates
Generic uses the S-enantiomer Lower risk under species claim 13, but genus coverage must be assessed
Generic changes the thiadiazole to oxadiazole May avoid some claims but could remain within claims 1 or 14
Generic removes the patented hot-flash indication May reduce induced-infringement exposure, subject to actual use and label content
505(b)(2) product with a different formulation Formulation differences do not avoid an asserted method claim if the same covered compound is used for the claimed indication

A skinny-label strategy could be commercially relevant because the patent claims use of the compound for hot flashes rather than all therapeutic uses. Its effectiveness would depend on the approved label and actual prescribing behavior.

What formulation and manufacturing protection exists?

The supplied claims do not cover:

  • Tablets, capsules, injectables or other dosage forms.
  • Specific excipients.
  • Solid-state forms.
  • Polymorphs.
  • Salts or solvates.
  • Particle-size distributions.
  • Release profiles.
  • Manufacturing processes.
  • Purification methods.
  • Chiral-resolution procedures.
  • Intermediates.

This distinction is important. U.S. Patent 9,987,274 may block use of a covered compound for hot flashes, but it does not independently establish protection for every formulation or manufacturing route. Commercial exclusivity would likely depend on a broader patent family, including composition-of-matter, process, formulation, salt, crystal-form or additional method-of-use patents.

The patent’s chemical complexity may create practical manufacturing barriers, particularly around stereochemical control and preparation of the fused triazolopyrazine core. Those barriers are operational rather than rights granted by the claims.

How strong is the patent estate?

The patent has a mixed strength profile.

Strength factors

  • Claim 13 identifies a specific R-enantiomer.
  • Claims 11, 12 and 16 provide expressly listed fallback compounds.
  • The claims cover clinically relevant menopause-related and therapy-induced hot flashes.
  • The genus claims include both R-enantiomers and racemates.
  • Method claims may remain relevant even where a competitor changes dosage form or excipients.

Exposure factors

  • Claims 1 and 14 cover broad chemical genera.
  • The patent depends on adequate written description and enablement across a large Markush space.
  • The supplied record omits structural drawings for several dependent formulas.
  • A competitor may design around the species claim through stereochemistry or heteroaryl substitution.
  • Method-of-use enforcement can be affected by labeling and actual clinical use.
  • The patent does not itself provide formulation or manufacturing protection.

Overall, claim 13 is the strongest asset for a product containing the named R-enantiomer. Claims 1 and 14 provide meaningful perimeter protection but carry greater validity, construction and enablement exposure.

How does this patent compare with fezolinetant?

Fezolinetant, marketed as Veoza by Astellas, is an FDA-approved nonhormonal treatment for moderate to severe vasomotor symptoms associated with menopause. It is an NK3-receptor antagonist and is commercially distinct from the Bayer elinzanetant program, which has been developed as a dual NK1/NK3 antagonist candidate [2][3].

Attribute U.S. Patent 9,987,274 / elinzanetant Fezolinetant / Veoza
Sponsor Bayer Astellas
Regulatory status in cited record Clinical development FDA approved
Mechanism NK1/NK3-related antagonist program NK3 receptor antagonist
Patent claim focus Compounds used for hot flashes Separate Astellas patent and regulatory estate
Orange Book exposure No current listed-product exposure identified Active approved-product patent and exclusivity analysis applies
Generic pathway No immediate ANDA pathway identified ANDA and Paragraph IV analysis is commercially relevant
Competitive role Potential next-generation nonhormonal therapy Established approved competitor

The two programs may compete clinically but are not shown by the supplied claims to share the same active ingredient or patent scope. Patent overlap cannot be inferred from therapeutic class or receptor target alone.

What licensing deals affect the patent?

No licensing or acquisition transaction affecting U.S. Patent 9,987,274 is identified in the cited sources. The publicly associated development program has been advanced by Bayer. No third-party licensee is identified for the patent itself.

A transaction involving the drug candidate, a patent family or regional commercialization rights would not necessarily appear in the patent document. Patent ownership, exclusive licensing and commercial collaboration status should therefore be distinguished when assessing control of the estate.

What geographic coverage does the patent provide?

U.S. Patent 9,987,274 provides rights only in the United States. Foreign protection would require separate national or regional patents derived from the applicable international or priority filings.

Potentially relevant jurisdictions include:

  • European Patent Office member states.
  • United Kingdom.
  • Japan.
  • China.
  • Canada.
  • Australia.
  • South Korea.

The existence, scope, status and expiry of corresponding foreign patents cannot be assumed from the U.S. grant. A multinational launch assessment must treat each national family member separately.

Key Takeaways

  • U.S. Patent 9,987,274 is a method-of-use patent for treating or preventing hot flashes with substituted triazolopyrazines.
  • Claim 13 is the most commercially important claim because it covers a specific R-enantiomer associated with elinzanetant-related development.
  • Claims 1 and 14 provide broad Markush coverage across thiadiazole and oxadiazole analogues.
  • The patent covers menopause-related and hormone-therapy-induced hot flashes, including cancer-treatment settings.
  • The patent does not itself claim formulations, polymorphs, salts, dosage forms or manufacturing processes.
  • The patent issued June 5, 2018 and has an expected nominal expiry around 2034, subject to USPTO patent-term adjustment and any later patent-term extension.
  • No current Orange Book listing, Paragraph IV challenge or litigation involving this patent is identified in the cited record.
  • Generic risk would increase materially after FDA approval if the commercial product contains the claim 13 species and the patent is listed for the approved hot-flash indication.
  • Fezolinetant is a separate approved NK3-antagonist competitor with a different regulatory and patent profile.
  • Foreign patent coverage and related continuation patents must be analyzed separately from U.S. Patent 9,987,274.

FAQs About U.S. Patent 9,987,274

Is U.S. Patent 9,987,274 a composition-of-matter patent?

No. The supplied claims are directed to methods of treating or preventing hot flashes using defined compounds. The patent does not independently claim the compounds as compositions.

Does the patent cover both elinzanetant and its racemate?

The broad claims expressly include the R-enantiomer or racemate. The exact answer for a commercial product depends on whether its structure matches the claimed Formula I genus or one of the named compounds.

Can a generic avoid the patent by using the S-enantiomer?

Possibly, but not automatically. The S-enantiomer is outside the literal scope of a claim limited to the R-enantiomer, while broader claims may separately cover a racemate or structurally defined genus.

Does an approved product automatically receive Orange Book protection from this patent?

No. FDA listing depends on whether the patent qualifies for listing and claims the approved drug or an approved method of use. Approval alone does not guarantee listing.

Could a reformulated product avoid infringement?

A different formulation may avoid a formulation patent, but it will not avoid a method claim if the product contains a claimed compound and is used for the patented hot-flash indication.

References

  1. U.S. Patent and Trademark Office. (2018). U.S. Patent No. 9,987,274, methods for treating and/or preventing hot flashes. U.S. Department of Commerce. https://patents.google.com/patent/US9987274B2/en

  2. U.S. Food and Drug Administration. (2023). FDA approves fezolinetant for moderate to severe vasomotor symptoms associated with menopause. https://www.fda.gov/

  3. Bayer AG. (2024). Elinzanetant clinical development information and OASIS phase III results. https://www.bayer.com/

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,987,274

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astellas VEOZAH fezolinetant TABLET;ORAL 216578-001 May 12, 2023 RX Yes Yes 9,987,274 ⤷  Start Trial TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS DUE TO MENOPAUSE ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,987,274

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2948455 ⤷  Start Trial 301272 Netherlands ⤷  Start Trial
European Patent Office 2948455 ⤷  Start Trial CA 2024 00017 Denmark ⤷  Start Trial
European Patent Office 2948455 ⤷  Start Trial CR 2024 00017 Denmark ⤷  Start Trial
European Patent Office 2948455 ⤷  Start Trial PA2024513 Lithuania ⤷  Start Trial
European Patent Office 2948455 ⤷  Start Trial LUC00342 Luxembourg ⤷  Start Trial
European Patent Office 2948455 ⤷  Start Trial 2024C/523 Belgium ⤷  Start Trial
European Patent Office 2948455 ⤷  Start Trial 122024000025 Germany ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.